




FIG. 1





FIG. 2

A.

Cohort A



B.




FIG. 3





FIG. 4

A.



B.





FIG. 5

A

.

Cohort C



B.




FIG. 6

7/15




FIG. 7





FIG. 8



^aCentral ctDNA testing was performed at screening to identify *KRAS* missense alterations, *NRAS* mutations, *BRAF* mutations (leading to V600X change), or *ERBB2/HER2* amplification.
ctDNA, circulating tumor DNA; DCR, disease control rate; DoR, duration of response; EGFRi, epidermal growth factor receptor inhibitor; ORR, objective response rate; PFS, progression-free survival; RP2D, recommended phase 2 dose.

FIG. 9




FIG. 10

11/15





FIG. 11



^aAll variants are mutations unless otherwise stated. ^bNo *MET* amplification was identified in this baseline assessment using ctDNA analyses. ^cMutations were detected in 1 patient each for *RB1*, *PTPN11*, *JAK2*, *FGFR2*, *BRCA1*, *BRCA2*, *ATM*, and *CDKN2A*; the patient with an *ALK* fusion had aggressive disease progression. ^dPresent as a single mutation in 1 patient. CR, complete response; ctDNA, circulating tumor DNA; PD, progressive disease; PR, partial response; SD, stable disease; SoD, sum of diameter; uPR, unconfirmed partial response.

FIG. 12



FIG. 13




FIG. 15